Get access

Metabolic syndrome abnormalities are associated with severity of anxiety and depression and with tricyclic antidepressant use

Authors


Arianne K.B. van Reedt Dortland, Leiden University Medical Centre, Department of Psychiatry, B1-P, PO Box 9600, 2300 RC, Leiden, the Netherlands.
E-mail: akbvanreedtdortland@lumc.nl

Abstract

van Reedt Dortland AKB, Giltay EJ, van Veen T, Zitman FG, Penninx BWJH. Metabolic syndrome abnormalities are associated with severity of anxiety and depression and with tricyclic antidepressant use.

Objective:  The metabolic syndrome (MetSyn) predisposes to cardiovascular disease and diabetes mellitus. There might also be an association between the MetSyn and anxiety and depression, but its nature is unclear. We aimed to investigate whether diagnosis, symptom severity and antidepressant use are associated with the MetSyn.

Method:  We addressed the odds for the MetSyn and its components among 1217 depressed and/or anxious subjects and 629 controls, and their associations with symptom severity and antidepressant use.

Results:  Symptom severity was positively associated with prevalence of the MetSyn, [adjusted odds ratio (OR) 2.21 for very severe depression: 95% confidence interval (CI): 1.06–4.64, = 0.04], which could be attributed to abdominal obesity and dyslipidemia. Tricyclic antidepressant (TCA) use also increased odds for the MetSyn (OR 2.30, 95% CI: 1.21–4.36, = 0.01), independent of depression severity.

Conclusion:  The most severely depressed people and TCA users more often have the MetSyn, which is driven by abdominal adiposity and dyslipidemia.

Get access to the full text of this article

Ancillary